European Archives - Page 1076 of 1201 - European Medical Journal

Continue
EMJ
25 May 2016

KEYNOTE-010: Pembrolizumab versus docetaxel in advanced PD-L1-positive NSCLC

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD…
EMJ
25 May 2016

ASCEND-2 and ASCEND-3 trials: Ceritinib in ALK-rearranged NSCLC with brain metastases

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD…
EMJ
25 May 2016

Immune checkpoint inhibitors, durvalumab plus tremelimumab, for non-small cell lung cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD…
EMJ
25 May 2016

Immunotherapy for hepatocellular carcinoma

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Su Pin Choo, MBBS…
EMJ
25 May 2016

Phase 3 LUX-H&N1 trial: Afatinib versus methotrexate for head and neck squamous cell carcinoma

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Makoto Tahara, MD…
EMJ
25 May 2016

Endocrine therapy in pregnant women with breast cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD…
EMJ
25 May 2016

Olaparib and bevacizumab: On the horizon for treating ovarian cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Suresh Kumarasamy, MBBS…
EMJ
25 May 2016

Tumour biomarker changes after neoadjuvant chemotherapy in breast cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD…
25 May 2016

From biologics to biosimilars

A biosimilar can be defined as a biological product that demonstrates no clinically meaningful differences to an approved biological product. At the…
25 May 2016

New Phase 3 Study Findings Show STELARA® Maintained Clinical Remission after One Year of Treatment in Patients with Moderate to Severe Crohn’s Disease

SAN DIEGO, May 23, 2016: Janssen Research & Development, LLC (Janssen) Phase 3 data presented for the first time at Digestive Disease Week® 2016 showed…
We’ve noticed you’re accessing
from North/South America.